Journal
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
Volume 175, Issue 6, Pages 2986-2995Publisher
HUMANA PRESS INC
DOI: 10.1007/s12010-014-1466-1
Keywords
Fermentation; Heparin; Sulfotransferase; Epimerase; Recombinant enzymes
Funding
- NIH [HL096972]
- National Natural Science Foundation of China [31171737]
- PRC [210208310507]
- Bioengineered Heparin Consortium
Ask authors/readers for more resources
Bioengineered heparin is being investigated as a potential substitute for the animal-sourced anticoagulant drug. One step in the current process to prepare bioengineered heparin involves the conversion of N-sulfo heparosan, rich in -> aEuro parts per thousand 4)GlcNS(1 -> aEuro parts per thousand 4) GlcA(1 -> aEuro parts per thousand sequences (where S is sulfo, GlcN is alpha-d-glucosamine, and GlcA is beta-d-glucuronic acid), to a critical intermediate, rich in -> aEuro parts per thousand 4)GlcNS(1 -> aEuro parts per thousand 4) IdoA2S(1 -> aEuro parts per thousand sequences (where S is sulfo and IdoA is alpha-l-iduronic acid), using 2-O-sulfotransferase (2-OST) and C5 epimerase (C-5-epi). Until now, these heparan sulfate biosynthetic enzymes have been expressed in Escherichia coli grown in shake flask culture as fusion proteins. The current study is focused on the high cell density fed-batch cultivation of recombinant E. coli strains expressing both enzymes. We report the high productivity expression of active 2-OST and C-5-epi enzymes of 6.0 and 2.2 mg/g dry cell weight, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available